▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Dan Carroll

TMFCane

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Recent Articles by Dan Carroll

Dec 13, 2013 by Dan Carroll

Merck and GE Cling to Gains Despite Dow's Struggles

Merck wins a thumbs-up from an FDA committee on its latest drug, pushing shares into the green.

Dec 12, 2013 by Dan Carroll

Merck's 2013 Leaves Questions Lingering for Investors

This top Dow health care stock has struggled through the patent cliff this year, but is Merck looking good heading into the final days of 2013?

Dec 12, 2013 by Dan Carroll

Cisco, UnitedHealth Lead the Dow's Struggling Stocks Down

A tough day for stocks has left investors sitting in the red into the afternoon trading session.

Dec 10, 2013 by Dan Carroll

Merck, Johnson & Johnson Slide on the Dow's Dip

Merck falls among a slow day for both Big Pharma and blue-chip stocks.

Dec 9, 2013 by Dan Carroll

McDonald's Sales Troubles Weighs Down the Dow's Gains

GE rises to continue a successful year-to-date surge despite the Dow's wobbly day.

Dec 7, 2013 by Dan Carroll

3 Big Impacts From Obamacare on America's Largest Health Insurers

In the wake of UnitedHealth's announcement that Obamacare could take a bite out of its earnings next year, here are three big ways that Obamacare could make waves -- for better and for worse -- in the insurance industry in 2014

Dec 7, 2013 by Dan Carroll

The 5 Fastest-Growing Countries in the World

From Peru to China, meet the surging economies that make up the five fastest-growing countries in the world.

Dec 7, 2013 by Dan Carroll

3 Budding Drug Superstars in This Big Pharma's Future

Can Bristol-Myers Squibb keep its amazing growth in 2013 going strong in the future? It'll rely on ballyhooed drugs like these to discover its future growth.

Dec 6, 2013 by Dan Carroll

Unemployment's Fall to 7% Fuels a Huge Day for the Dow

Intel jumps after an upgrade today, while Disney keeps up its unrivaled run.

Dec 6, 2013 by Dan Carroll

Can This Cardiac King Find Its Nerve?

St. Jude Medical's a leader in neuromodulation, but with rivals crowding out the space, it's looking to move into the next generation of devices.

Dec 6, 2013 by Dan Carroll

Can These 3 Diving Device Stocks Deliver in 2014?

Volcano, Intuitive Surgical, and Edwards Lifesciences have taken a hit this year. Should you trust that a turnaround is on the way?

Dec 5, 2013 by Dan Carroll

Microsoft's Plunge Leads the Dow's Wobbly Dip

Pfizer, JPMorgan both decline on a day of falling stocks across the market.

Dec 4, 2013 by Dan Carroll

UnitedHealth Falls Victim to the Dow's Drop and Obamacare

America's largest insurer falls 0.5% after detailing the costs of Obamacare, while Microsoft beats the Dow's plunge.

Dec 3, 2013 by Dan Carroll

Merck's Slide Helps Drag Down the Dow's Triple-Digit Drop

Merck and Pfizer both plunge into the red on a day of huge losses on the Dow Jones.

Dec 3, 2013 by Dan Carroll

Can Merck Sustain 2013's Healthy Climb in the New Year?

This Dow Jones health-care standout has surged this year, but is the worst of the patent cliff over for Merck?

Dec 2, 2013 by Dan Carroll

Wall Street Turns Negative on 3M as the Dow Bucks Good News Again

The ISM's PMI shows an uptick in manufacturing, but that's not enough for the Dow Jones to hit the red. Meanwhile, UnitedHealth misses analyst estimates on next year's earnings while 3M plunges.

Nov 30, 2013 by Dan Carroll

November's 3 Biggest Biotech Busts

Sarepta's huge drop leads a field of monthly losers that includes Aegerion's drop and Immunogen's plunge.

Nov 29, 2013 by Dan Carroll

Brazil's Big Opportunity Can't Wait for This Health Care Leader

Smith & Nephew follows in the footsteps of Medtronic and Stryker in pushing overseas for its newest growth opportunities.

Nov 29, 2013 by Dan Carroll

3 Surging Biotechs That Made Investors Rich in November

ViroPharma, Idenix, and Geron all boomed in a big way for shareholders over the past month.

Nov 28, 2013 by Dan Carroll

Will This Top Dow Health-Care Stock Stay Healthy in 2014?

Pfizer's boomed in 2013, and with the patent cliff's worries beginning to subside, the stock could be ready to keep rolling in the new year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services